Patrick Johnson appointed to Aviceda Therapeutics’ board of directors

Appointments

Private clinical-stage biotech, Aviceda Therapeutics has announced that it has appointed Patrick Johnson to its board of directors.

Johnson has vast experience of business leadership with entrepreneurial expertise, and has seen various pharmaceutical and biotechnology companies maximise the value of their brands and realise the potential of their innovations. His experience spans various areas of corporate operations, including global M&A, business development, strategic transactions, fundraising, clinical operations, scientific research and corporate finance.

Mohamed A Genead MD CEO and president of Aviceda Therapeutics, commented: “We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond. Patrick will bring significant industry expertise, and his strategic counsel will be invaluable to Aviceda as we continue to advance our technology platform in late-stage clinical development for patients with geographic atrophy (GA) due to age-related macular degeneration and broader therapeutic applications.”

Johnson added: “It is a privilege to join Aviceda’s board as the organisation advances towards delivering new treatment options for people living with retinal diseases, many of whom have been significantly underserved for decades. I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialisation.”

Ishwaria Subbiah appointed SCRI’s executive director for Cancer Care Equity & Professional Wellness

Oncology research organisation, Sarah Cannon Research Institute (SCRI) has announced that Ishwaria Subbiah MD MS, has been appointed to the role of executive director of cancer care equity and professional wellness.

LEON appoints Dr Setu Kasera as CSO

LEON has announced the appointment of Dr Setu Kasera as its new chief scientific officer (CSO) effective 15 June 2023.

Alex C Sapir appointed as Fulcrum Therapeutics’ CEO

Clinical stage biopharmaceutical company, Fulcrum Therapeutics, has announced the appointment of Alex C Sapir as CEO and president effective 1 July 2023.

Optibrium appoints Dr Hamed Tabatabaei Ghomi as head of research

Optibrium has announced the appointment of Dr Hamed Tabatabaei Ghomi as head of research, this is the latest appointment in a series of senior level hires. Ghomi brings with him experience of strategic and industrial research in the bioinformatics space, as well as a positive academic record.

Roz Bekker appointed managing director of Janssen UK and Ireland

The Janssen pharmaceutical companies, part of Johnson & Johnson (J&J), has announced the appointment of Roz Bekker as the new managing director of Janssen UK and Ireland.

Ishwaria Subbiah appointed SCRI’s executive director for Cancer Care Equity & Professional Wellness

LEON appoints Dr Setu Kasera as CSO

Alex C Sapir appointed as Fulcrum Therapeutics’ CEO

Optibrium appoints Dr Hamed Tabatabaei Ghomi as head of research

Roz Bekker appointed managing director of Janssen UK and Ireland

Pharmafocus

Categories

Social Footprints